Literature DB >> 24282295

Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.

Tanya Stoyanova1, Aaron R Cooper, Justin M Drake, Xian Liu, Andrew J Armstrong, Kenneth J Pienta, Hong Zhang, Donald B Kohn, Jiaoti Huang, Owen N Witte, Andrew S Goldstein.   

Abstract

The relationship between the cells that initiate cancer and the cancer stem-like cells that propagate tumors has been poorly defined. In a human prostate tissue transformation model, basal cells expressing the oncogenes Myc and myristoylated AKT can initiate heterogeneous tumors. Tumors contain features of acinar-type adenocarcinoma with elevated eIF4E-driven protein translation and squamous cell carcinoma marked by activated beta-catenin. Lentiviral integration site analysis revealed that alternative histological phenotypes can be clonally derived from a common cell of origin. In advanced disease, adenocarcinoma can be propagated by self-renewing tumor cells with an androgen receptor-low immature luminal phenotype in the absence of basal-like cells. These data indicate that advanced prostate adenocarcinoma initiated in basal cells can be maintained by luminal-like tumor-propagating cells. Determining the cells that maintain human prostate adenocarcinoma and the signaling pathways characterizing these tumor-propagating cells is critical for developing effective therapeutic strategies against this population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24282295      PMCID: PMC3864278          DOI: 10.1073/pnas.1320565110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status.

Authors:  Renea A Taylor; Roxanne Toivanen; Mark Frydenberg; John Pedersen; Laurence Harewood; Anne T Collins; Norman J Maitland; Gail P Risbridger
Journal:  Stem Cells       Date:  2012-06       Impact factor: 6.277

2.  Prospective identification of tumorigenic prostate cancer stem cells.

Authors:  Anne T Collins; Paul A Berry; Catherine Hyde; Michael J Stower; Norman J Maitland
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.

Authors:  Hongbing Chen; Yin Sun; Chengyu Wu; Clara E Magyar; Xinmin Li; Liang Cheng; Jorge L Yao; Steven Shen; Adeboye O Osunkoya; Chaozhao Liang; Jiaoti Huang
Journal:  Endocr Relat Cancer       Date:  2012-05-24       Impact factor: 5.678

4.  Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

Authors:  Josep Domingo-Domenech; Samuel J Vidal; Veronica Rodriguez-Bravo; Mireia Castillo-Martin; S Aidan Quinn; Ruth Rodriguez-Barrueco; Dennis M Bonal; Elizabeth Charytonowicz; Nataliya Gladoun; Janis de la Iglesia-Vicente; Daniel P Petrylak; Mitchell C Benson; Jose M Silva; Carlos Cordon-Cardo
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

5.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

Authors:  Brian J P Huntly; Hirokazu Shigematsu; Kenji Deguchi; Benjamin H Lee; Shinichi Mizuno; Nicky Duclos; Rebecca Rowan; Sonia Amaral; David Curley; Ifor R Williams; Koichi Akashi; D Gary Gilliland
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

6.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

7.  eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.

Authors:  Jeremy R Graff; Bruce W Konicek; Rebecca L Lynch; Chad A Dumstorf; Michele S Dowless; Ann M McNulty; Stephen H Parsons; Leslie H Brail; Bruce M Colligan; Jonathan W Koop; Bernadette M Hurst; James A Deddens; Blake L Neubauer; Louis F Stancato; Harry W Carter; Larry E Douglass; Julia H Carter
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

8.  Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas.

Authors:  Arnout G Schepers; Hugo J Snippert; Daniel E Stange; Maaike van den Born; Johan H van Es; Marc van de Wetering; Hans Clevers
Journal:  Science       Date:  2012-08-01       Impact factor: 47.728

9.  Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling.

Authors:  Yang Zong; Jiaoti Huang; Devipriya Sankarasharma; Teppei Morikawa; Masashi Fukayama; Jonathan I Epstein; Kiran K Chada; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

10.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

View more
  77 in total

1.  Distinct phases of human prostate cancer initiation and progression can be driven by different cell-types.

Authors:  Tanya Stoyanova; Andrew S Goldstein
Journal:  Cancer Cell Microenviron       Date:  2014

Review 2.  Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Authors:  Sergej Skvortsov; Ira-Ida Skvortsova; Dean G Tang; Anna Dubrovska
Journal:  Stem Cells       Date:  2018-08-27       Impact factor: 6.277

3.  PIP5K1α inhibition as a therapeutic strategy for prostate cancer.

Authors:  Justin M Drake; Jiaoti Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-12       Impact factor: 11.205

4.  Inflammation promotes prostate differentiation.

Authors:  Xian Liu; Andrew S Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-23       Impact factor: 11.205

5.  Targeting RET Kinase in Neuroendocrine Prostate Cancer.

Authors:  Halena R VanDeusen; Johnny R Ramroop; Katherine L Morel; Song Yi Bae; Anjali V Sheahan; Zoi Sychev; Nathan A Lau; Larry C Cheng; Victor M Tan; Zhen Li; Ashley Petersen; John K Lee; Jung Wook Park; Rendong Yang; Justin H Hwang; Ilsa Coleman; Owen N Witte; Colm Morrissey; Eva Corey; Peter S Nelson; Leigh Ellis; Justin M Drake
Journal:  Mol Cancer Res       Date:  2020-05-27       Impact factor: 5.852

6.  Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.

Authors:  Tanya Stoyanova; Mireille Riedinger; Shu Lin; Claire M Faltermeier; Bryan A Smith; Kelvin X Zhang; Catherine C Going; Andrew S Goldstein; John K Lee; Justin M Drake; Meghan A Rice; En-Chi Hsu; Behdokht Nowroozizadeh; Brandon Castor; Sandra Y Orellana; Steven M Blum; Donghui Cheng; Kenneth J Pienta; Robert E Reiter; Sharon J Pitteri; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-30       Impact factor: 11.205

Review 7.  Prostate Luminal Progenitor Cells in Development and Cancer.

Authors:  Dingxiao Zhang; Shuhong Zhao; Xinyun Li; Jason S Kirk; Dean G Tang
Journal:  Trends Cancer       Date:  2018-10-01

8.  Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.

Authors:  Jung Wook Park; John K Lee; Katherine M Sheu; Liang Wang; Nikolas G Balanis; Kim Nguyen; Bryan A Smith; Chen Cheng; Brandon L Tsai; Donghui Cheng; Jiaoti Huang; Siavash K Kurdistani; Thomas G Graeber; Owen N Witte
Journal:  Science       Date:  2018-10-05       Impact factor: 47.728

9.  Cancer origins-genetics rules the day.

Authors:  Michael S Kareta; Julien Sage
Journal:  Science       Date:  2018-10-05       Impact factor: 47.728

10.  Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.

Authors:  Andrew C Hsieh; Hao G Nguyen; Lexiaochuan Wen; Merritt P Edlind; Peter R Carroll; Won Kim; Davide Ruggero
Journal:  Sci Signal       Date:  2015-11-17       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.